BML Investment Partners Takes 5.0% Stake in Reneo Pharma

TL;DR

**BML Investment Partners just bought 5% of Reneo Pharma, signaling a bullish institutional bet.**

AI Summary

BML Investment Partners, L.P., a Delaware-based investment firm, has reported a new passive ownership stake in Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM). As of January 10, 2024, BML Investment Partners, L.P. holds 1,000,000 shares of Reneo's common stock, representing 5.0% of the company's outstanding shares. This filing indicates a significant new institutional investor believes in Reneo's future, which could signal increased confidence and potentially attract other investors to the stock.

Why It Matters

This new institutional investment by BML Investment Partners, L.P. could be seen as a vote of confidence in Reneo Pharmaceuticals, potentially boosting investor sentiment and stock price.

Risk Assessment

Risk Level: low — This filing indicates a new institutional investor, which generally reduces risk by diversifying the shareholder base and signaling confidence.

Analyst Insight

A smart investor would monitor Reneo Pharmaceuticals for further institutional buying or positive news, as this filing suggests growing confidence in the company's prospects.

Key Numbers

• 1,000,000 — Shares acquired (Total shares of Reneo Pharmaceuticals, Inc. common stock held by BML Investment Partners, L.P.)
• 5.0% — Ownership percentage (Percentage of Reneo Pharmaceuticals, Inc.'s common stock owned by BML Investment Partners, L.P.)
• $0.0001 — Par value per share (Par value of Reneo Pharmaceuticals, Inc. common stock)

Key Players & Entities

• BML Investment Partners, L.P. (company) — the reporting person acquiring shares
• Reneo Pharmaceuticals, Inc. (company) — the subject company whose shares were acquired
• Delaware (company) — place of organization for BML Investment Partners, L.P.
• January 10, 2024 (date) — date of the event requiring the filing

Forward-Looking Statements

• Reneo Pharmaceuticals' stock price may experience a short-term positive reaction due to increased institutional interest. (Reneo Pharmaceuticals, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• bml13g.htm (SC 13G) — 75KB
• 0001616824-24-000011.txt ( ) — 76KB

(a)

Item 1(a). Name of Issuer: Reneo Pharmaceuticals, Inc.

(b)

Item 1(b). Address of Issuer's Principal Executive Offices: 18575 Jamboree Road, Suite 275-S , Irvine , CA

(a)

Item 2(a). Name of Person Filing: BML Investment Partners, L.P.

(b)

Item 2(b). Address of Principal Business Office or, if none, Residence: 65 E. Cedar - Suite 2 Zionsville, IN 46077

(c)

Item 2(c). Citizenship: Delaware

(d)

Item 2(d). Title of Class of Securities: Common Stock, par value $0.0001 per share

(e)

Item 2(e). CUSIP Number: 75974E103 Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n): (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E); (f) Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ . Item 4. (a) Amount beneficially owned: 1,694,229 (b) Percent of class: 5.1% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 330 000 (ii) Shared power to vote or to direct the vote: 1,364,229 (iii) Sole power to dispose or to direct the disposition of: 330 000 (iv) Shared power to dispose or to direct the disposition of: 1,364,229 Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent

View Full Filing

View this SC 13G filing on SEC EDGAR